Atezolizumab(Synonyms: 阿特珠单抗; MPDL3280A)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Atezolizumab (Synonyms: 阿特珠单抗; MPDL3280A)

Atezolizumab (MPDL3280A) 是一种人源化单克隆抗体 IgG1，抵抗程序性死亡因子配体1 (PD-L1)，用于癌症研究。

Atezolizumab(Synonyms: 阿特珠单抗; MPDL3280A)

Atezolizumab Chemical Structure

CAS No. : 1380723-44-3

规格 价格 是否有货 数量
1 mg ￥2700 In-stock
5 mg ￥5700 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

生物活性

Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

体外研究
(In Vitro)

Atezolizumab (0, 2.5, 5, 10, 20, and 40 µg/ml; 24 hours; HOS and 143B cells) inhibits proliferation and induces immune-independent apoptosis of osteosarcoma cells[1].
Atezolizumab impairs the function of mitochondria to cause the imbalance between oxidants and antioxidants. Atezolizumab induces mitochondria-related apoptosis of osteosarcoma cells by activating JNK pathway. Atezolizumab (10 µg/ml; 24 hours; HOS and 143B cells) induces autophagy in osteosarcoma cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

144590.50

CAS 号

1380723-44-3
中文名称

阿特珠单抗；阿替利珠单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Cha E, et al. PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol. 2015 Jun;42(3):484-7.

    [2]. Liu Z, et al. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma. Cell Death Dis. 2021;12(2):164. Published 2021 Feb 8.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务